Eddie Rashan

As promised, a 🧵 on our recent article now out in @NatureSMB! Co-led with @AbbyBartlett_ @Pagliarini_Lab @JudithSimcox, we find ACAD10/11 are NOT like other acyl-CoA dehydrogenases and instead catabolize atypical lipids called 4-hydroxy acids 🤯#lipidtime doi.org/10.1038/s41594…

Just published @NEJM Marked and durable reduction of LDL cholesterol with one shot PCSK9 gene base editing @skathire nejm.org/doi/full/10.10…

Excited to share our new publication: "Exome-wide association study for blood lipids in 1,158,017 individuals from diverse populations." nature.com/articles/s4158… This study explores how multi-ancestry DNA sequencing has identified rare coding variants that influence blood lipids and atherosclerotic risk. Highlights include: • Discovery of rare coding variants across more than 1 million participants • Identification of novel lipid-associated genes • Insights into variant annotation and recessive associations • Potential therapeutic targets for coronary artery disease • The power of global biobank collaboration I extend my gratitude to all collaborators, participants, and consortium teams who made this research possible. I am proud to be part of this effort. Special thanks to my mentors, Drs. Yan Sun, Peter Wilson, @patrick_ellinor, and @pnatarajanmd, for their guidance and support throughout this work! For more details, see the previous thread: x.com/skoyamamd/stat…

This one is hard to see. The NIH Early Independence Award, one of the most competitive grants in the country for young scientists, will not go forward in FY2026. NIH says this is due to “administrative changes to funding opportunity processing and delays in approvals.”

Excited to share our new @biorxivpreprint from the @BradyLab & @PaulTitchenell lab on MASH, phosphatidylcholine metabolism, and copper biology with @JaclynE_x8 & biorxiv.org/content/10.648…

Please share!!: If you know of any Afghan women/girls who were accepted to a university but couldn’t get a scholarship or find funding, please DM me. We’re working on a few things to approach this.

Retatrutide phase 3 obesity trial just came out and the results are genuinely insane: - 28.3% bodyweight lost on 12mg over 80 weeks - 70.3 pounds on avg. or 31.9 kg - 45.3% of patients hit 30%+ weight loss (this is bariatric surgery territory) - 30.3% weight loss (85 lbs) at 104 weeks in higher-BMI patients - 65.3% of 12mg patients dropped below the obesity BMI threshold - 19% loss on 4mg over 80 weeks (47.2 lbs) with fewer dropouts than placebo (4.1% vs 4.9%) - significant drops in blood pressure, triglycerides, non-HDL cholesterol, waist circumference, and hsCRP - no cardiac or liver signals Retatrutide is going to completely overshadow tirzepatide and semaglutide, and take the throne as the best-selling drug of all time.

@NaOHBartfield You don't find the deafening screech soothing?

hey boston people why does the green line sound like that

Our paper just went live on @NatureAging. Peroxisomes are understudied & regarded as organelles with functions ancillary to those of the mitochondria. We shift this paradigm by demonstrating how peroxisomes actively guide organelles cascades & maintain them to drive healthy aging

Happy to share our recent paper, in which we show that DKC1 is both a therapeutic target and a diagnostic biomarker in colorectal cancer. DKC1 is a critical part of the telomerase complex, and when elevated, it fuels cancer progression. Link: nature.com/articles/s4146…

New review from our group taking a critical look at OxPhos as a cancer target......and suggestions for where the field goes next. Published in @Biochem_Journal portlandpress.com/biochemj/artic…

Presented at #ASGCT2026: A neuroepithelial tumor occurred in a child who had previously received AAV gene therapy for mucopolysaccharidosis type I. Analysis of tumor tissue showed the integration of rearranged AAV vector elements in the gene PLAG1. Read the full report: nej.md/4cXAAPt @ASGCTherapy

Human whole-blood NAD+ levels do not vary with age or lifestyle interventions dlvr.it/TSXX7P

Aconitase 2 the rescue: A safeguard against excess mitochondrial citrate dlvr.it/TSTbwG

Why is there such obsession with extending lifespan when the bigger issue is that average healthspan is 65 years and there are no data (except in super-centenarians) that longer lifespan = longer healthspan (known as compression of morbidity)?

New out this week from our lab in @NatMetabolism. We measured dynamic aspartate changes following mitochondrial inhibition, finding that SDH inhibition causes a counterintuitive rebound effect mediated by succinate impairing pyrimidine synthesis. nature.com/articles/s4225…

The franchise continues in 2026. 67 years on the market and we still wonder how metformin works. Congrats to Nav and team nature.com/articles/s4225…

ApoE4 carries lipids, drives AD risk, and makes microglia mad! But how important are lipids in this process? Our new preprint shows lipid-bound ApoE4 drives lipid droplet expansion, but lipid-free ApoE4 drives inflammation! biorxiv.org/cgi/content/sh…

Check out our Spotlight in @MolecularCell on @lydfinley lab's recent work on Aconitase 2 and its protective role against impaired cell fitness and ISR activation due to mitochondrial citrate accumulation authors.elsevier.com/c/1n3Nn3vVUPZO…

ABRCMS was my 1st conference. I attended with these two at a critical point in my career and my experience there cemented my trajectory in science. This is us at ABRCMS in my 1st year as faculty. Please use the link below to donate and keep ABRCMS going for future generations!

It's not often that I do microscopy. Lipophilic tracers look so cool!